Interpretation of the National Comprehensive Cancer Network Clinical Practice Guidelines for Malignant Tumors in HIV-infected Patients (version 1, 2023) in non-small cell lung cancer

doi:10.19983/j.issn.2096-8493.20230037

Abstract

Abstract:

The National Comprehensive Cancer Network (NCCN) is an academic alliance of 32 leading cancer centers, and it develops clinical guidelines for various malignant tumors every year. In 2023, the first edition of the Clinical Practice Guidelines for Malignant Tumors in HIV-infected Patients was published. Compared to the 2021 edition, updates have been made in the screening, diagnosis, and immunotherapy of lung cancer in HIV infected individuals. This article will interpret and discuss the updated content of non-small cell lung cancer, to provide references for clinical practice.

Key words: HIV infections, Carcinoma, non-small-cell lung, Guidebooks

CLC Number:

R734

Li Leilei, Gao Jingtao, Wang Lin, Song Yanzheng. Interpretation of the National Comprehensive Cancer Network Clinical Practice Guidelines for Malignant Tumors in HIV-infected Patients (version 1, 2023) in non-small cell lung cancer[J]. Journal of Tuberculosis and Lung Disease , 2023, 4(3): 198-202. doi: 10.19983/j.issn.2096-8493.20230037

References 36

[1]	Reid E, Suneja G, Al-Rohil R, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines) Cancer in People with HIV (Version 1. 2023)[EB/OL]. (2022-12-20) [2023-05-04]. https://www.nccn.org/professionals/physician_gls/pdf/hiv.pdf.
[2]	Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer, 2008, 123(1): 187-194. doi:10.1002/ijc.23487. doi: 10.1002/ijc.23487 pmid: 18435450
[3]	Robbins HA, Pfeiffer RM, Shiels MS, et al. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst, 2015, 107(4): dju503. doi:10.1093/jnci/dju503. doi: 10.1093/jnci/dju503
[4]	National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409. doi:10.1056/NEJMoa1102873. doi: 10.1056/NEJMoa1102873 URL
[5]	National Lung Screening Trial Research Team, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med, 2013, 368(21): 1980-1991. doi:10.1056/NEJMoa1209120. doi: 10.1056/NEJMoa1209120 URL
[6]	Davison JM, Subramaniam RM, Surasi DS, et al. FDG PET/CT in patients with HIV. AJR Am J Roentgenol, 2011, 197(2): 284-294. doi:10.2214/AJR.10.6332. doi: 10.2214/AJR.10.6332 URL
[7]	Goodman PC. Radiographic Assessment of HIV-Associated Diseases. HIV InSite 2006[EB/OL]. [2023-05-04]. https://hivinsite.ucsf.edu/InSite?page=kb-04-01-16#S1X.
[8]	Allen CM, Al-Jahdali HH, Irion KL, et al. Imaging lung manifestations of HIV/AIDS. Ann Thorac Med, 2010, 5(4): 201-216. doi:10.4103/1817-1737.69106. doi: 10.4103/1817-1737.69106 pmid: 20981180
[9]	Strategies for Management of Antiretroviral Therapy SMART Study Group, El-Sadr WM, Lundgren J, et al. CD4⁺ count-guided interruption of antiretroviral treatment. N Engl J Med, 2006, 355(22): 2283-2296. doi:10.1056/NEJMoa062360. doi: 10.1056/NEJMoa062360 URL
[10]	Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol, 2007, 165(10): 1143-1153. doi:10.1093/aje/kwm017. doi: 10.1093/aje/kwm017 pmid: 17344204
[11]	Gérard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr, 2002, 30(5): 478-484. doi:10.1097/00126334-200208150-00003. doi: 10.1097/00126334-200208150-00003 URL
[12]	Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents[EB/OL]. [2023-05-04]. https://aidsetc.org/resource/guidelines-use-antiretroviral-agents-hiv-1-infected-adults-and-adolescents.
[13]	Calkins KL, Chander G, Joshu CE, et al. Immune Status and Associated Mortality After Cancer Treatment Among Indivi-duals With HIV in the Antiretroviral Therapy Era. JAMA Oncol, 2020, 6(2): 227-235. doi:10.1001/jamaoncol.2019.4648. doi: 10.1001/jamaoncol.2019.4648 pmid: 31804663
[14]	Sparano JA, Hu X, Wiernik PH, et al. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma treated with chemotherapy. J Natl Cancer Inst, 1997, 89(4): 301-307. doi:10.1093/jnci/89.4.301. doi: 10.1093/jnci/89.4.301 pmid: 9048834
[15]	Ngidi S, Magula N, Sartorius B, et al. Incidence of chemotherapy-induced neutropenia in HIV-infected and uninfected patients with breast cancer receiving neoadjuvant chemotherapy. S Afr Med J, 2017, 107(7): 595-601. doi:10.7196/SAMJ.2017.v107i7.12309. doi: 10.7196/SAMJ.2017.v107i7.12309 URL
[16]	Park J, Kim TM, Hwang JH, et al. Risk factors for febrile neutropenia during chemotherapy for HIV-related lymphoma. J Korean Med Sci, 2012, 27(12): 1468-1471. doi:10.3346/jkms.2012.27.12.1468. doi: 10.3346/jkms.2012.27.12.1468 pmid: 23255844
[17]	Alfa-Wali M, Dalla Pria A, Nelson M, et al. Surgical excision alone for stage T1 anal verge cancers in people living with HIV. Eur J Surg Oncol, 2016, 42(6): 813-816. doi:10.1016/j.ejso.2016.02.253. doi: 10.1016/j.ejso.2016.02.253 pmid: 27012999
[18]	Leeds IL, Alturki H, Canner JK, et al. Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review. World J Surg Oncol, 2016, 14(1): 208. doi:10.1186/s12957-016-0970-x. doi: 10.1186/s12957-016-0970-x pmid: 27495294
[19]	Lefèvre JH, Corte H, Tiret E, et al. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol, 2012, 19(13): 4186-4192. doi:10.1245/s10434-012-2485-1. doi: 10.1245/s10434-012-2485-1 pmid: 22825769
[20]	Izadmehr S, Leapman M, Hobbs AR, et al. Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer. Int Urol Nephrol, 2016, 48(10):1639-1645. doi:10.1007/s11255-016-1338-4. doi: 10.1007/s11255-016-1338-4 pmid: 27318820
[21]	Silberstein JL, Parsons JK, Palazzi-Churas K, et al. Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus. Prostate Cancer Prostatic Dis, 2010, 13(4): 328-332. doi:10.1038/pcan.2010.35. doi: 10.1038/pcan.2010.35
[22]	Sigel C, Cavalcanti MS, Daniel T, et al. Clinicopathologic Features of Colorectal Carcinoma in HIV-Positive Patients. Cancer Epidemiol Biomarkers Prev, 2016, 25(7): 1098-1104. doi:10.1158/1055-9965.EPI-15-1179. doi: 10.1158/1055-9965.EPI-15-1179 URL
[23]	Wang L, Chen Y, Wang Y, et al. Lung cancer surgery in HIV-infected patients: An analysis of postoperative complications and long-term survival. Thorac Cancer, 2020, 11(8): 2146-2154. doi:10.1111/1759-7714.13519. doi: 10.1111/1759-7714.13519 URL
[24]	Wang L, Wu L, Liu J, et al. Prognostic nomogram for surgery of lung cancer in HIV-infected patients. J Thorac Dis, 2021, 13(1):76-81. doi:10.21037/jtd-20-2268. doi: 10.21037/jtd-20-2268 pmid: 33569187
[25]	Sparano JA, Wiernik PH, Hu X, et al. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma. Med Oncol, 1998, 15(1):50-57. doi:10.1007/BF02787345. doi: 10.1007/BF02787345 pmid: 9643531
[26]	Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol, 2011, 12(9): 905-912. doi:10.1016/S1470-2045(11)70056-0. doi: 10.1016/S1470-2045(11)70056-0 pmid: 21570912
[27]	Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis, 2014, 59(1): 106-114. doi:10.1093/cid/ciu174. doi: 10.1093/cid/ciu174 pmid: 24642555
[28]	Larson KB, Wang K, Delille C, et al. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet, 2014, 53(10): 865-872. doi:10.1007/s40262-014-0167-9. doi: 10.1007/s40262-014-0167-9 pmid: 25164142
[29]	Deeken JF, Beumer JH, Anders NM, et al. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. Cancer Chemother Pharmacol, 2015, 76(4): 813-819. doi:10.1007/s00280-015-2856-y. doi: 10.1007/s00280-015-2856-y URL
[30]	Casado JL, Machuca I, Bañón S, et al. Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy. Antivir Ther, 2015, 20(7): 773-777. doi:10.3851/IMP2961. doi: 10.3851/IMP2961 pmid: 25879675
[31]	Torres HA, Rallapalli V, Saxena A, et al. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect, 2014, 20(10): O672-679. doi:10.1111/1469-0691.12589. doi: 10.1111/1469-0691.12589 URL
[32]	Shah NJ, Al-Shbool G, Blackburn M, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer, 2019, 7(1): 353. doi:10.1186/s40425-019-0771-1. doi: 10.1186/s40425-019-0771-1 pmid: 31847881
[33]	Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD 4 count on the outcome and treatment tole-rance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys, 1999, 44(1): 127-131. doi:10.1016/s0360-3016(98)00528-8. doi: 10.1016/s0360-3016(98)00528-8 URL
[34]	Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology, 1994, 193(1): 251-254. doi:10.1148/radiology.193.1.8090901. doi: 10.1148/radiology.193.1.8090901 pmid: 8090901
[35]	Kim JH, Sarani B, Orkin BA, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum, 2001, 44(10): 1496-1502. doi:10.1007/BF02234605. doi: 10.1007/BF02234605 pmid: 11598480
[36]	Alongi F, Giaj-Levra N, Sciascia S, et al. Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncol, 2017, 18(7): e379-e393. doi:10.1016/S1470-2045(17)30440-0. doi: 10.1016/S1470-2045(17)30440-0 URL